Actively Recruiting
Post Marketing Surveillance for Finerenone in Adults With Chronic Heart Failure and LVEF 40% or Higher in South Korea
Led by Bayer · Updated on 2026-02-03
300
Participants Needed
1
Research Sites
39 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are observing people in South Korea who have chronic heart failure with a left ventricular ejection fraction (LVEF) of 40% or higher and are receiving finerenone. The study aims to understand the safety and effectiveness of finerenone, a medicine that targets a receptor in the body to reduce harm to the heart, kidneys, and blood vessels. This medication is already approved and prescribed by doctors, and the study focuses on gathering data from everyday medical care without changing treatments. Participants will receive finerenone as prescribed by their doctors during their regular medical visits. The study collects data from those who are starting finerenone treatment for chronic heart failure with LVEF of 40% or greater. There are no additional tests or visits required for the study; information is gathered from medical records and interviews during routine care. During the one-year period after joining the study or until participants decide to leave, researchers will monitor any side effects or health issues that may be related to finerenone. They will also track how satisfied doctors are with the treatment over time, including symptom improvement, quality of life, and overall health. Changes in finerenone dosing will be recorded as part of the evaluation of how well the medicine works.
CONDITIONS
Brief Title
A Study to Learn More About How Safe Finerenone is and How Well it Works in Adults With Chronic Heart Failure in South Korea
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults aged 19 years or older
- Able to provide informed consent or have a legal representative provide consent
- Finerenone-naïve patients prescribed finerenone for chronic heart failure with LVEF 40% or higher
You will not qualify if you...
- Known allergy or hypersensitivity to finerenone or any of its ingredients
- Participation in other investigational programs with treatments outside routine clinical practice
- Contraindications according to local finerenone labeling, including NYHA classes II-IV
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person) for screening and enrollment
Duration - Up to 12 months from baseline
Participants prescribed finerenone for chronic heart failure are observed to collect safety and treatment satisfaction data.
Visits at 1, 3, 6, and 12 months after baseline
Trial Site Locations
Total: 1 location
1
Many Locations
Multiple Locations, South Korea
Actively Recruiting
Research Team
B
Bayer Clinical Trials Contact
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here